Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AUT00201 in Healthy Volunteers
NCT04158453Phase 1Completed
- Sponsor
- Autifony Therapeutics
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing AUT00201 with Placebo (2 arms). Primary endpoint: Percent of subjects with treatment-related adverse events. Started Oct 2019; status: completed.
02
Drugs
AUT00201
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04158453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158453.